Isis Pharmaceuticals (ISIS): Today's Featured Drugs Laggard

Editor's Note: Any reference to TheStreet Ratings and its underlying recommendation does not reflect the opinion of TheStreet, Inc. or any of its contributors including Jim Cramer or Stephanie Link.

Isis Pharmaceuticals ( ISIS) pushed the Drugs industry lower today making it today's featured Drugs laggard. The industry as a whole closed the day up 2.4%. By the end of trading, Isis Pharmaceuticals fell $0.77 (-1.5%) to $51.39 on average volume. Throughout the day, 1,268,165 shares of Isis Pharmaceuticals exchanged hands as compared to its average daily volume of 1,259,300 shares. The stock ranged in price between $50.71-$52.65 after having opened the day at $52.00 as compared to the previous trading day's close of $52.16. Other companies within the Drugs industry that declined today were: IntelliPharmaCeutics International ( IPCI), down 9.7%, iBio ( IBIO), down 6.0%, Alcobra ( ADHD), down 5.2% and La Jolla Pharmaceutical ( LJPC), down 5.1%.

Isis Pharmaceuticals, Inc. engages in the discovery and development of antisense drugs using novel drug discovery platform. Isis Pharmaceuticals has a market cap of $6.1 billion and is part of the health care sector. Shares are up 30.9% year to date as of the close of trading on Friday. Currently there are 4 analysts that rate Isis Pharmaceuticals a buy, 1 analyst rates it a sell, and 3 rate it a hold.

TheStreet Ratings rates Isis Pharmaceuticals as a hold. The company's strengths can be seen in multiple areas, such as its revenue growth, solid stock price performance and impressive record of earnings per share growth. However, as a counter to these strengths, we find that the company's return on equity has been disappointing.

On the positive front, Aoxing Pharmaceutical Company ( AXN), up 55.9%, Prana Biotechnology ( PRAN), up 39.3%, Forest Laboratories ( FRX), up 27.5% and Skystar Bio-Pharmaceutical Company ( SKBI), up 13.4% , were all gainers within the drugs industry with Gilead ( GILD) being today's featured drugs industry leader.

For investors not wanting singular stock exposure, ETFs may be of interest. Investors who are bullish on the drugs industry could consider SPDR S&P Pharmaceuticals ETF ( XPH) while those bearish on the drugs industry could consider ProShares UltraShort Nasdaq Biotech ( BIS).

STOCKS TO BUY: TheStreet Quant Ratings has identified a handful of stocks that can potentially TRIPLE in the next 12-months. Learn more.

If you liked this article you might like

Jim Cramer's 'Mad Money' Recap: Here's This Week's Game Plan

Isis Pharmaceuticals Changes Its Name

Isis Pharmaceuticals Changes Its Name

Highlighted Post-Market Laggard: ISIS Pharmaceuticals (ISIS)

Jim Cramer's 'Mad Money' Recap: Stocks Gain When Analysts Curb Negativity

ISIS Pharmaceuticals (ISIS) Weak On High Volume